| Dr Jeanette Kamell Mitchell, MD | |
|
55 Rolling Oaks Dr Ste 200, Thousand Oaks, CA 91361-1010 | |
| (805) 497-7529 | |
| (805) 494-3486 |
| Full Name | Dr Jeanette Kamell Mitchell |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 17 Years |
| Location | 55 Rolling Oaks Dr Ste 200, Thousand Oaks, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154567410 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | A106113 (California) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| J Robert West Md Inc | 8729990973 | 136 |
News Archive
A vaccine for one of the most lethal cancers, advanced melanoma, has shown improved response rates and progression-free survival for patients when combined with the immunotherapy drug, Interleukin-2, according to researchers from The University of Texas M. D. Anderson Cancer Center.
New research published online in The FASEB Journal suggests that a novel therapeutic target called LPCAT2 may prove effective against pain that is not receptive to the current treatments.
Sanofi presented results from the landmark ORIGIN trial (Outcome Reduction with Initial Glargine Intervention) at the American Diabetes Association 72nd Scientific sessions. The key findings showed that, compared to standard care, Lantus(insulin glargine [rDNA] injection) had no statistically significant positive or negative impact on cardiovascular (CV) outcomes versus standard care during the study period and that there was no association between insulin glargine use and increased risk of any cancer.
The microbes living in the guts of males and females react differently to diet, even when the diets are identical, according to a study by scientists from The University of Texas at Austin and six other institutions published this week in the journal Nature Communications.
› Verified 8 days ago
| Entity Name | J Robert West Md Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932154788 PECOS PAC ID: 8729990973 Enrollment ID: O20031105000239 |
News Archive
A vaccine for one of the most lethal cancers, advanced melanoma, has shown improved response rates and progression-free survival for patients when combined with the immunotherapy drug, Interleukin-2, according to researchers from The University of Texas M. D. Anderson Cancer Center.
New research published online in The FASEB Journal suggests that a novel therapeutic target called LPCAT2 may prove effective against pain that is not receptive to the current treatments.
Sanofi presented results from the landmark ORIGIN trial (Outcome Reduction with Initial Glargine Intervention) at the American Diabetes Association 72nd Scientific sessions. The key findings showed that, compared to standard care, Lantus(insulin glargine [rDNA] injection) had no statistically significant positive or negative impact on cardiovascular (CV) outcomes versus standard care during the study period and that there was no association between insulin glargine use and increased risk of any cancer.
The microbes living in the guts of males and females react differently to diet, even when the diets are identical, according to a study by scientists from The University of Texas at Austin and six other institutions published this week in the journal Nature Communications.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jeanette Kamell Mitchell, MD 2285 Corporate Cir, Ste 200, Henderson, NV 89074-7759 Ph: (702) 360-2763 | Dr Jeanette Kamell Mitchell, MD 55 Rolling Oaks Dr Ste 200, Thousand Oaks, CA 91361-1010 Ph: (805) 497-7529 |
News Archive
A vaccine for one of the most lethal cancers, advanced melanoma, has shown improved response rates and progression-free survival for patients when combined with the immunotherapy drug, Interleukin-2, according to researchers from The University of Texas M. D. Anderson Cancer Center.
New research published online in The FASEB Journal suggests that a novel therapeutic target called LPCAT2 may prove effective against pain that is not receptive to the current treatments.
Sanofi presented results from the landmark ORIGIN trial (Outcome Reduction with Initial Glargine Intervention) at the American Diabetes Association 72nd Scientific sessions. The key findings showed that, compared to standard care, Lantus(insulin glargine [rDNA] injection) had no statistically significant positive or negative impact on cardiovascular (CV) outcomes versus standard care during the study period and that there was no association between insulin glargine use and increased risk of any cancer.
The microbes living in the guts of males and females react differently to diet, even when the diets are identical, according to a study by scientists from The University of Texas at Austin and six other institutions published this week in the journal Nature Communications.
› Verified 8 days ago
Dr. Seth R Stevens, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 267 W Hillcrest Dr, Thousand Oaks, CA 91360 Phone: 805-497-1694 Fax: 805-373-7493 | |
Dr. Navid Ezra, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3095 Old Conejo Rd, Suite 200, Thousand Oaks, CA 91320 Phone: 805-222-5803 | |
Sean Condon, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 267 W Hillcrest Dr, Thousand Oaks, CA 91360 Phone: 805-497-1694 | |
Robert A Gold, MD Dermatology Medicare: Medicare Enrolled Practice Location: 45 North Erbes Road, Thousand Oaks, CA 91362 Phone: 818-404-3200 | |
Dr. Nima Milani-nejad, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 100 Moody Ct Ste 200, Thousand Oaks, CA 91360 Phone: 805-418-3500 Fax: 805-418-3505 | |
Dr. Azita Simoni, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 425 Haaland Dr Ste 204, Thousand Oaks, CA 91361 Phone: 805-497-8080 Fax: 805-497-8806 |